A phase 1 trial testing ceralasertib (an early DNA damage response inhibitor) combined with durvalumab produced promising early results in recurrent or metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. The program tests complementary mechanisms—checkpoint inhibition paired with radiosensitization/DDR stress—aimed at improving response durability. Separately, research points to immune-evasive tumor ecosystems that can be attacked more broadly: Memorial Sloan Kettering researchers reported preclinical data for uPAR-targeting CAR T-cell approaches in multiple solid-tumor contexts. By engineering T cells to target supportive cells marked by uPAR, the strategy aims to expand the range of solid tumors vulnerable to CAR T therapy. Together, the updates highlight how sponsors are pairing immunotherapy with precision biology—either by stacking mechanisms in early clinical programs or by identifying microenvironment targets that can broaden patient eligibility.